#CMSC2018 – Gains in Functional Abilities Seen in Lemtrada-treated MS Patients Over Six Years, CARE-MS II Extension Study Shows
Patients with active relapsing-remitting multiple sclerosis (MS) continue to show improvement ā lesser functional disability across a variety of measures ā and often without the need for continuous treatment after takingĀ LemtradaĀ for two years, according to six-year results from the CARE-MS II extension study. These results were shared in a…